Rubicon科室讲课幻灯

1、Rubicon 14 支撑(zh chng)导管共十九页UnderstandingChronic Total Occlusions Clinical Overview看看慢性(mn xng)全闭塞病变的情况共十九页CTO-慢性(mn xng)全闭塞性病变临床需求CTOs在下肢手术中的发病约为30-40%；将近40%的CTO需要多种技术以穿越病变1新技术的发展推动了血管腔内治疗的CTO治疗2 没有CTO治疗的金标准(biozhn)3 多种治疗方案实验性及错误的方法器械选择决定于熟练程度和使用的便利性主要挑战产品表现不佳和临床效果不佳器械外廓大，精确度有限，学习曲线长额外的手术时间和复杂性1. 2

2、010-2011 Global PI Tracking Study; 2. True lumen re-entry devices facilitate subintimal angioplasty and stenting of CTOs Jacobs, D., et al, Journal of Vasc Surgery, Jun 2006 3. PI MAB 2011 Feedback共十九页CTO解剖(jipu)大部分SFA长段闭塞，通常可以在造影下看到近端像树桩一样的头端，然后远端血管不同程度显影(xin yng)，或来自股深动脉的侧支。Crossing Peripheral CTO

3、s. Tony S. Das, MD. Endovascular Today, March 2006Results from case studies are not predictive of results in other cases. Results in other cases may vary.共十九页严重肢体缺血(CLI)患者(hunzh)的临床考量共十九页CLI不仅仅只是(zhsh)针对BTKCLI不仅仅是由BTK血管病变引起的，为了重建足部的血运，我们需要考虑整个下肢的血管状况流入道病变 主要是在SFA，也有在髂动脉. (CLI累及髂动脉少见，如累及髂动脉时多数患者会有严重的

4、间歇性跛行)流出道病变 主要是在胫动脉和腓动脉，但通常扩展至足部动脉一个417例患者的研究表明，每位患者在膝关节和足部之间的血管平均(pngjn)有6.9个病灶共十九页病灶(bngzo)分布Vascular Involvement in Diabetic Subjects with Ischemic Foot Ulcer: A New Morphologic Categorization of Disease SeverityL. Graziani et al. Eur J Vasc Endovasc Surg 33, 453e460 (2007)共十九页BTK闭塞最为常见，但SFA的病变更值

5、得(zh d)关注Lesion Distribution (417 patients, 2893 lesions)共十九页无法穿越(chun yu)? 无法治疗! 穿刺和穿越病变是最令人沮丧(jsng)，最耗时的！如果你无法到达和穿越病变，就无法进行治疗！共十九页RubiconTM 14支撑(zh chng)导管共十九页Rubicon 14-产品(chnpn)参数All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by

6、 or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations.共十九页Rubicon 14支撑导管突破(tp)强硬病变超低的头端通过外廓帮助通

7、过复杂(fz)病变强硬的远端头端和杆身材料提供优秀的推送性三个不透射线标记点提供优秀的可视性共十九页0.018” (0.46 mm) 头端通过外廓新一代尼龙头端和杆身材料三个不透射线标记点对比明显的紫色头端透明接头(ji tu)和近端杆身材料远端亲水涂层135 cm和150cm长度提高复杂病变进入和通过性加强推送性，提高 病变通过性能优秀的可视性更易辨识，简化导丝的装载(zhungzi)提高血流回渗的可视性？提高通过性多种长度选择，适用于近端及远端病变Rubicon 14支撑导管关键特性与利益利益特性 共十九页Rubicon 14支撑(zh chng)导管产品定位突破(tp)强硬病变Tackl

8、e Tougher LesionsRubicon 14支撑导管促进/提高致密或闭塞性病变的通过-Facilitates crossing of tight occlusions.0.018”的头端通过外廓，强硬的新一代远侧头端技术提供了优秀的推送能力，加上三个不透射线标记点，使得Rubicon具有卓越的病变通过性为你在应对致密或闭塞病变时提供最大的帮助！共十九页CXITM Support Catheter-COOK0.018”及0.035”系统90,135,150cm三种长度可供选择直头和弯头两种头端形状杆身3个，头端1个，共4个不透射线(shxin)标记点远端40cm杆身有亲水涂层杆身金属编

9、织结构价格：RMB5000共十九页TrailBlazer Support Catheter-Covidien0.014”,0.018”及0.035”系统65,90,135,150cm工作(gngzu)长度直头头端外廓：0.035”系统-0.040”0.018”系统-0.022”0.014”系统-0.019”三个不透射线标记点远端40cm亲水涂层价格：RMB3000+共十九页Rubicon 14支撑(zh chng)导管更好的推送性Average measurements taken by Boston Scientific. N = 10. Data on file. Bench test r

10、esults may not necessarily be indicative of clinical performance.Push is defined as a measure of the shafts ability to transmit force to distal tip in straight-line configuration. All cited trademarks are the properties of their respective owners. TrailBlazer TM is a registered trademark of ev3. Qui

11、ck Cross is a product owned by Spectranetics; Minnie is a product owned by Vascular solutions.共十九页Rubicon 14支撑导管(dogun)超低的头端通过外廓Average measurements taken by Boston Scientific. N = 10. Data on file. Bench test results may not necessarily be indicative of clinical performance.共十九页内容摘要Rubicon 14 支撑导管。流出道病变 主要是在胫动脉和腓动脉，但通常扩展至足部动脉。如果(